Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Aquestive Therapeutics, Inc.

Market Cap 591M 515M 477M 447M 838M 55.75B 843M 5.66B 2.19B 27.44B 2.22B 2.17B 95.29B P/E 2026 *
-11.6x
P/E 2027 * -12.1x
Enterprise Value 506M 441M 409M 382M 717M 47.73B 722M 4.85B 1.88B 23.49B 1.9B 1.86B 81.58B EV / Sales 2026 *
10x
EV / Sales 2027 * 8.22x
Free-Float
96.9%
Yield 2026 *
-
Yield 2027 * -
1 day+6.32%
1 week+12.95%
Current month+17.16%
1 month+12.95%
3 months+18.34%
6 months-18.79%
Current year-27.09%
1 week 4.12
Extreme 4.125
4.74
1 month 3.85
Extreme 3.85
4.74
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 17/05/2022
Director of Finance/CFO 67 31/12/2020
Compliance Officer - 02/04/2026
Director TitleAgeSince
Chairman 72 01/04/2024
Director/Board Member 60 01/01/2004
Director/Board Member 50 17/05/2022
Date Insider Type Main position Quantity % Market Cap.
06-15Sell

Chief Executive Officer

-25,000 0.0199%
06-10Free

Director

50,500 0.0403%
06-10Other

Director

50,500 0.0403%
Change 5-day change 1-year change 3-year change Capi.($)
+6.32%+12.95%+44.92%+129.76% 591M
-1.21%-3.04%+44.03%+143.07% 980B
-2.48%-5.18%+52.47%+39.15% 550B
-2.14%-4.94%+16.83%+57.08% 382B
+0.25%-3.09%+23.33%+16.04% 316B
+0.61%-1.69%+27.35%+13.73% 272B
+0.22%-3.10%+24.67%+30.49% 268B
+4.59%+1.98%-38.43%-46.26% 199B
-1.19%-4.95%+16.68%+47.69% 182B
-1.35%-1.46%+14.06%+59.26% 154B
Average +0.36%-1.53%+22.59%+49.00% 330.29B
Weighted average by Cap. -0.78%-3.67%+29.49%+63.32%

Financials

2026 *2027 *
Net sales 50.52M 44.04M 40.79M 38.19M 71.62M 4.77B 72.05M 484M 188M 2.35B 190M 186M 8.15B 71.91M 62.7M 58.07M 54.36M 102M 6.79B 103M 689M 267M 3.34B 270M 264M 11.6B
Net income -50.65M -44.16M -40.9M -38.29M -71.8M -4.78B -72.24M -485M -188M -2.35B -190M -186M -8.17B -47.99M -41.85M -38.76M -36.28M -68.04M -4.53B -68.45M -460M -178M -2.23B -180M -176M -7.74B
Net Debt -85M -74.11M -68.64M -64.25M -121M -8.02B -121M -814M -316M -3.95B -319M -312M -13.71B -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
18/06/26 4.710 $ +6.32% 3,138,143
17/06/26 4.430 $ +3.99% 1,977,231
16/06/26 4.260 $ +0.95% 1,054,290
15/06/26 4.220 $ +1.20% 1,309,618
12/06/26 4.170 $ -0.95% 1,223,124
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.710USD
Average target price
8.889USD
Spread / Average Target
+88.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!